Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial

Dan Ziegler, Phillip A Low, William J Litchy, Andrew J M Boulton, Aaron I Vinik, Roy Freeman, Rustem Samigullin, Hans Tritschler, Ullrich Munzel, Joachim Maus, Klemens Schütte, Peter J Dyck, Dan Ziegler, Phillip A Low, William J Litchy, Andrew J M Boulton, Aaron I Vinik, Roy Freeman, Rustem Samigullin, Hans Tritschler, Ullrich Munzel, Joachim Maus, Klemens Schütte, Peter J Dyck

Abstract

Objective: To evaluate the efficacy and safety of α-lipoic acid (ALA) over 4 years in mild-to-moderate diabetic distal symmetric sensorimotor polyneuropathy (DSPN). RESEARCH DESIGN AND METHODS In a multicenter randomized double-blind parallel-group trial, 460 diabetic patients with mild-to-moderate DSPN were randomly assigned to oral treatment with 600 mg ALA once daily (n = 233) or placebo (n = 227) for 4 years. Primary end point was a composite score (Neuropathy Impairment Score [NIS]-Lower Limbs [NIS-LL] and seven neurophysiologic tests). Secondary outcome measures included NIS, NIS-LL, nerve conduction, and quantitative sensory tests (QSTs).

Results: Change in primary end point from baseline to 4 years showed no significant difference between treatment groups (P = 0.105). Change from baseline was significantly better with ALA than placebo for NIS (P = 0.028), NIS-LL (P = 0.05), and NIS-LL muscular weakness subscore (P = 0.045). More patients showed a clinically meaningful improvement and fewer showed progression of NIS (P = 0.013) and NIS-LL (P = 0.025) with ALA than with placebo. Nerve conduction and QST results did not significantly worsen with placebo. Global assessment of treatment tolerability and discontinuations due to lack of tolerability did not differ between the groups. The rates of serious adverse events were higher on ALA (38.1%) than on placebo (28.0%).

Conclusions: Four-year treatment with ALA in mild-to-moderate DSPN did not influence the primary composite end point but resulted in a clinically meaningful improvement and prevention of progression of neuropathic impairments and was well tolerated. Because the primary composite end point did not deteriorate significantly in placebo-treated subjects, secondary prevention of its progression by ALA according to the trial design was not feasible.

Trial registration: ClinicalTrials.gov NCT00977483.

Figures

Figure 1
Figure 1
Patient disposition.

References

    1. Boulton AJM, Vinik AI, Arezzo JC, et al. ; American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28:956–962
    1. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A; KORA Study Group. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008;31:464–469
    1. Patel A, MacMahon S, Chalmers J, et al. ; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–2572
    1. Duckworth W, Abraira C, Moritz T, et al. ; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129–139
    1. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580–591
    1. Ziegler D, Luft D. Clinical trials for drugs against diabetic neuropathy: can we combine scientific needs with clinical practicalities? Int Rev Neurobiol 2002;50:431–463
    1. Ametov AS, Barinov A, Dyck PJ, et al. ; SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with α-lipoic acid: the SYDNEY trial. Diabetes Care 2003;26:770–776
    1. Ziegler D, Ametov A, Barinov A, et al. . Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006;29:2365–2370
    1. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a meta-analysis. Diabet Med 2004;21:114–121
    1. Ziegler D, Sohr CGH, Nourooz-Zadeh J. Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care 2004;27:2178–2183
    1. Bril V, Hirose T, Tomioka S, Buchanan R; Ranirestat Study Group. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 2009;32:1256–1260
    1. Ropper AH, Gorson KC, Gooch CL, et al. . Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. Ann Neurol 2009;65:386–393
    1. Vinik AI, Bril V, Kempler P, et al. ; MBBQ Study Group. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther 2005;27:1164–1180
    1. Boulton AJM. Whither clinical research in diabetic sensorimotor peripheral neuropathy? Problems of end point selection for clinical trials. Diabetes Care 2007;30:2752–2753
    1. Dyck PJ, Norell JE, Tritschler H, et al. . Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity. Diabetes Care 2007;30:2619–2625
    1. Dyck PJ, Davies JL, Litchy WJ, O’Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997;49:229–239
    1. Peripheral Nerve Society. Diabetic polyneuropathy in controlled clinical trials: Consensus Report of the Peripheral Nerve Society. Ann Neurol 1995;38:478–482
    1. Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1988;11:21–32
    1. Dyck PJ, Karnes JL, O’Brien PC, Litchy WJ, Low PA, Melton LJ, 3rd. The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. Neurology 1992;42:1164–1170
    1. Šidák Z. Rectangular confidence regions for the means of multivariate normal distributions. J Am Stat Assoc 1967;62:626–633
    1. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010;152:726–732
    1. Tesfaye S, Tandan R, Bastyr EJ, 3rd, Kles KA, Skljarevski V, Price KL; Ruboxistaurin Study Group. Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials. Diabetes Care 2007;30:2626–2632
    1. Sola S, Mir MQ, Cheema FA, et al. . Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005;111:343–348
    1. Koh EH, Lee WJ, Lee SA, et al. Effects of alpha-lipoic acid on body weight in obese subjects. Am J Med 2011;124:e1–e8
    1. Rathmann W, Haastert B, Delling B, Gries FA, Giani G. Postmarketing surveillance of adverse drug reactions: a correlational study approach using multiple data sources. Pharmacoepidemiol Drug Saf 1998;7:51–57

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi